Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
168 hedge funds and large institutions have $617M invested in Eagle Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 59 increasing their positions, 61 reducing their positions, and 23 closing their positions.
3% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 61
5% less funds holding
Funds holding: 176 → 168 (-8)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
23% less capital invested
Capital invested by funds: $802M → $617M (-$185M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
78% less call options, than puts
Call options by funds: $795K | Put options by funds: $3.59M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$12.8M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$9.92M |
| 3 |
Goldman Sachs
New York
|
+$9.49M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$8.17M |
| 5 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$7.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HEC
Hudson Executive Capital
New York
|
-$39.8M |
| 2 |
BlackRock
New York
|
-$6.86M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$4.67M |
| 4 |
MCM
Matarin Capital Management
New York
|
-$4.1M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$3.36M |
EGRX Hedge Fund Activity: Q1 2020 in Review
168 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2020, worth a combined $617M — down 23% from $802M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of EGRX and 18 opened new positions — a net loss of 5 holders — while 61 trimmed existing stakes and 59 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $12.8M. The largest seller was Hudson Executive Capital, exiting entirely with an estimated $39.8M sold.
- 168 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2020, down from 176 in Q4 2019.
- Funds reported $617M of Eagle Pharmaceuticals, Inc. stock for Q1 2020, down 23% quarter-over-quarter.
- 18 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2020 and 23 closed out, a net change of -5 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q1 2020 was Tang Capital Management, an estimated $12.8M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q1 2020 was Hudson Executive Capital, an estimated $39.8M sold.
Based on aggregated 13F filings for Q1 2020.